Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma

Annals of Surgical Oncology

Volumn 21, Issue 7, 2014, Pages 2310-2317

  Koo, Bon Seok ^a   Kim, Jin Man ^a   Seo, Sung Tae ^a   Yoon, Young Hoon ^a   Kwon, Ki Ryun ^a   Kim, Sung Ha ^a   Kwon, Hye Won ^b   Bae, Won Jin ^c   Lim, Young Chang ^d  

^a Chungnam National University College of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

^d Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN A; MET PROTEIN, HUMAN; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PAPILLARY THYROID MICROCARCINOMA; SUBCLINICAL CENTRAL LYMPH NODE METASTASIS; THYROID CARCINOMA; UPREGULATION; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; PROGNOSIS; SECONDARY; THYROID TUMOR; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84902134247     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3553-5     Document Type: Article

References (34)

1. Hedinger C, William ED, Sobin LH. Histological typing of thyroid tumors. Vol 11. Berlin: Springer; 1988.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-7.
3. Pearce EN, Braverman LE. Papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab. 2004;89:3710-2.
4. Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399-407.
5. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106:524-31.
6. So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung MK. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148:526-31.
7. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol. 2008;214:283-93.
8. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-25.
9. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2005;53:35-69.
10. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006;119:477-83.
11. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mansel RE, Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 2005;16:723-38.
12. Yücel OT, Sungur A, Kaya S. c-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases. Otolaryngol Head Neck Surg. 2004;130:698-703.
13. Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benvenga S, Trovato M. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization. Histol Histopathol. 2012;27:113-21.
14. Jin L, Fuchs A, Schnitt SJ, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 1997;79:749-60.
15. Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis GL. Over-expression of HGF and c-MET are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2000;53:635-44.
16. Lloyd R, De Lellis R, Heitz P, Eng C. World Health Organization Classification of Tumours: pathology and genetics of tumours of the endocrine organs. Lyon: IARC Press; 2004.
17. Xie LQ, Bian LJ, Li Z, Li Y, Li ZX, Li B. Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol. 2010;17:1927-36.
18. Shaha AR, Tuttle RM, Shah JP. Papillary microcarcinoma of the thyroid. J Surg Oncol. 2007;95:532-3.
19. Shaha AR. Complications of neck dissection for thyroid cancer. Ann Surg Oncol. 2008;15:397-9.
20. Paccione RJ, Miyazaki H, Patel V, Waseem A, Gutkind JS, Zehner ZE, Yeudall WA. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther. 2008;7:2894-903.
21. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744-53.
22. Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ, Cerutti JM. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res. 2008;14:4735-42.
23. Klein N, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 1999;161:41-9.
24. Ide T, Kitajima Y, Miyoshi A, et al. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer. 2006;119:2750-9.
25. Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated hepatocyte growth factor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res. 2006;12:4876-81.
26. Murai M, Shen X, Huang L, et al. Overexpression of c-Met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. Int J Oncol. 2004;25:831-40.
27. Gentile A, Trusolino L, Comoglio PM. The met tyrosine kinase receptor in development and cancer. Cancer Metas Rev. 2008;27:85-94.
28. Chen BK, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Liang SB, Sonobe H. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol Res Pract. 1999;195:427-33.
29. Ruco LP, Ranalli T, Marzullo A, Bianco P, Prat M, Comoglio PM, Baroni CD. Expression of Met protein in thyroid tumours. J Pathol. 1996;180:266-70.
30. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA. 2003;100:12718-23.
31. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEFG-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005;201:1089-99.
32. Hirakawa S. From tumor lymphangiogenesis to lymphvascular niche. Cancer Sci. 2009;100;983-9.
33. Mei L, Lin H, Ma S, Ji P, Xie D, Yu J. Vascular endothelial growth factor-A and -C: expression and correlations with lymphatic metastasis and prognosis in colorectal cancer. Med Oncol. 2011;28:151-8.
34. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196:1497-506.